CVS Health Co. (NYSE:CVS) Shares Bought by Capital International Sarl

Capital International Sarl grew its stake in CVS Health Co. (NYSE:CVS - Free Report) by 75.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,151 shares of the pharmacy operator's stock after acquiring an additional 20,306 shares during the period. Capital International Sarl's holdings in CVS Health were worth $2,117,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of CVS. EagleClaw Capital Managment LLC raised its holdings in CVS Health by 3.4% in the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock worth $275,000 after acquiring an additional 200 shares during the last quarter. Manchester Capital Management LLC boosted its position in shares of CVS Health by 4.8% during the fourth quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator's stock valued at $200,000 after buying an additional 204 shares during the last quarter. Angeles Investment Advisors LLC increased its holdings in CVS Health by 3.7% in the 4th quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock worth $256,000 after buying an additional 204 shares in the last quarter. Rogco LP lifted its stake in CVS Health by 3.2% during the 4th quarter. Rogco LP now owns 6,752 shares of the pharmacy operator's stock valued at $303,000 after acquiring an additional 210 shares during the period. Finally, Cozad Asset Management Inc. boosted its holdings in shares of CVS Health by 3.7% during the 4th quarter. Cozad Asset Management Inc. now owns 6,532 shares of the pharmacy operator's stock valued at $293,000 after acquiring an additional 233 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on CVS shares. Mizuho lifted their target price on shares of CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Morgan Stanley reaffirmed an "overweight" rating on shares of CVS Health in a report on Tuesday, April 15th. Barclays raised their target price on CVS Health from $71.00 to $73.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. StockNews.com upgraded shares of CVS Health from a "sell" rating to a "hold" rating in a research note on Thursday, February 13th. Finally, Edward Jones upgraded shares of CVS Health from a "hold" rating to a "buy" rating in a research report on Thursday, January 30th. Four equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and a consensus price target of $71.83.

Insiders Place Their Bets

In other news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael F. Mahoney acquired 30,000 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now owns 39,356 shares in the company, valued at $2,625,045.20. This represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.22% of the company's stock.

CVS Health Trading Up 0.2 %

Shares of NYSE:CVS traded up $0.13 on Wednesday, hitting $65.58. 10,463,527 shares of the company's stock were exchanged, compared to its average volume of 11,827,130. The stock has a market capitalization of $82.68 billion, a price-to-earnings ratio of 17.92, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $71.45. The business's 50 day simple moving average is $66.48 and its two-hundred day simple moving average is $58.77.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.06%. The ex-dividend date is Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.